EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma

Junyi Chen iD, Yuyang Liu, Jinxin Lan iD, Hongyu Liu iD, Qingyun Tang, Ze Li, Xiaoguang Qiu, Wentao Hu iD, Jiaxin Xie, Yaping Feng, Lilin Qin, Xin Zhang and 2 more

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14802 ↗

At a glance

Journal article in CNS Neuroscience & Therapeutics, 2024. Written by Junyi Chen and 13 co-authors. Institution: Medical School of Chinese PLA, Beijing, China. Major MEDLINE topics: Brain Neoplasms, Collagen Type VI, Electric Stimulation Therapy, Glioblastoma. Cited 18 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Glioblastoma multiforme (GBM) is the most aggressive primary brain malignancy. Novel therapeutic modalities like tumor electric field therapy (TEFT) have shown promise, but underlying mechanisms remain unclear. The extracellular matrix (ECM) is implicated in GBM progression, warranting investigation into TEFT‐ECM interplay.

Methods

T98G cells were treated with TEFT (200 kHz, 2.2 V/m) for 72 h. Collagen type VI alpha 1 (COL6A1) was identified as hub gene via comprehensive bioinformatic analysis based on RNA sequencing (RNA‐seq) and public glioma datasets. TEFT intervention models were established using T98G and Ln229 cell lines. Pre‐TEFT and post‐TEFT GBM tissues were collected for further validation. Focal adhesion pathway activity was assessed by western blot. Functional partners of COL6A1 were identified and validated by co‐localization and survival analysis.

Results

TEFT altered ECM‐related gene expression in T98G cells, including the hub gene COL6A1. COL6A1 was upregulated in GBM and associated with poor prognosis. Muti‐database GBM single‐cell analysis revealed high‐COL6A1 expression predominantly in malignant cell subpopulations. Differential expression and functional enrichment analyses suggested COL6A1 might be involved in ECM organization and focal adhesion. Western blot (WB), immunofluorescence (IF), and co‐immunoprecipitation (Co‐IP) experiments revealed that TEFT significantly inhibited expression of COL6A1, hindering its interaction with ITGA5, consequently suppressing the FAK/Paxillin/AKT pathway activity. These results suggested that TEFT might exert its antitumor effects by downregulating COL6A1 and thereby inhibiting the activity of the focal adhesion pathway.

Conclusion

TEFT could remodel the ECM of GBM cells by downregulating COL6A1 expression and inhibiting focal adhesion pathway. COL6A1 could interact with ITGA5 and activate the focal adhesion pathway, suggesting that it might be a potential therapeutic target mediating the antitumor effects of TEFT.

Subjects

MeSH terms (MEDLINE)

Brain NeoplasmsCollagen Type VIElectric Stimulation TherapyGlioblastomaAnimalsHumansMiceCell Line, TumorMice, Nude

Author keywords

COL6A1extracellular matrixglioblastoma multiformetumor electric field therapy

Substances

Col6a1 protein, humanCollagen Type VI

Authors and institutions

  • Medical School of Chinese PLA, Beijing, China.
  • Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China.
  • Department of Neurosurgery, 920th Hospital of Joint Logistics Support Force, Kunming, China.
  • School of Medicine, Nankai University, Tianjin, China.
  • Department of Neurosurgery, Hainan Hospital of Chinese PLA General Hospital, Hainan, China.
  • Department of Gastroenterology, 920th Hospital of Joint Logistics Support Force, Kunming, China.

ORCID profiles: Junyi Chen, Jinxin Lan, Hongyu Liu, Wentao Hu, Jialin Liu

Funding

  • National Natural Science Foundation of China

Cite

APA

Chen, J., Liu, Y., Lan, J., Liu, H., Tang, Q., Li, Z., Qiu, X., Hu, W., Xie, J., Feng, Y., Qin, L., Zhang, X., Liu, J., & Chen, L. (2024). Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14802

Vancouver

Chen J, Liu Y, Lan J, Liu H, Tang Q, Li Z, et al. Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14802

BibTeX
@article{Chen2024,
  author = {Chen, Junyi and Liu, Yuyang and Lan, Jinxin and Liu, Hongyu and Tang, Qingyun and Li, Ze and Qiu, Xiaoguang and Hu, Wentao and Xie, Jiaxin and Feng, Yaping and Qin, Lilin and Zhang, Xin and Liu, Jialin and Chen, Ling},
  title = {Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14802}
}
Start for free →